Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

PD-L1 Expression Is An Independent Predictor Of Favorable Outcome In Patients With Localized Esophageal Adenocarcinoma

D. Kollmann, D. Ignatova, J. Jedamzik, Yun-Tsan Chang, G. Jomrich, A. Baierl, D. Kazakov, M. Michal, L. French, W. Hoetzenecker, T. Schatton, R. Asari, M. Preusser, M. Gnant, E. Guenova, S. Schoppmann
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
ABSTRACT Background. The outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) remains poor. The programmed cell-death-protein-1 (PD-1), a co-inhibitory receptor primarily expressed by T-cells, represents a potential new therapeutic target. PD-1, PD-1 ligand 1 (PD-L1), and PD-L2 expression have all been described as prognostic factors in a variety of cancers. Their expression patterns in AEG, however, are poorly understood. We analyzed PD-L1, PD-L2 and PD-1 expression by tumor-infiltrating lymphocytes (TILs) and cancer-cells in tumor-biospecimens in AEG-patients. Methods. 168 patients who underwent esophagectomy because of AEG between 1992–2011 were included in this study. PD-L1, PD-L2 and PD-1 expression were evaluated by immunohistochemistry and correlated with various clinicopathological parameters, disease-free survival (DFS) and long-term overall survival (OS). Results. PD-L1 expression by cancer-cells (cancer-cell-PD-L1+) was found in 43.5% of patients whereas PD-L1 expression by TILs (TILs-PD-L1+) was observed in 69%. PD-L2 expression by cancer-cells and TILs was only found in 3.5% and 1.8%, respectively. Additionally, 77.4% of tumors contained PD-1+-cancer-cells and 81% PD-1+-TILs. Patients with increased expression of PD-1 by cancer-cells and TILs showed significantly reduced OS and DFS, as determined by univariate, but not multivariate analysis. Expression of PD-L1 by cancer-cells was found to be an independent predictor for improved DFS (p = 0.038) and OS (p = 0.042) in multivariate analysis. Conclusions. Cancer cells and TILs displayed PD-L1 expression in around 50% and PD-1 expression in around 80% of tumor-biospecimens obtained from AEG patients. Expression of PD-L1 is an independent predictor of favorable outcome in AEG, whereas PD-1 expression is associated with worse outcome and advanced tumor stage.
This paper references
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
E. Lipson (2013)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]
J. Ferlay (2013)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
L. Chen (2004)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
A. Wakita (2017)
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
S. Derks (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
S. Kleffel (2015)
The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
A. Kinter (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi (2005)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Q. Gao (2009)
Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8C tumor infiltrating lymphocytes
H Chang (2016)
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
D. Cunningham (2008)
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
Z. Mo (2016)
B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.
Lujun Chen (2014)
Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
S. Wang (2003)
Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci
S Tsutsumi (2017)
R: A language and environment for statistical computing.
R. Team (2014)
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection.
S. Subudhi (2004)
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
Kaiyan Chen (2016)
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
D. Kollmann (2017)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer
J. Ferlay (2013)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
R. H. Thompson (2006)
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Y. Xia (2016)
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
R. Droeser (2013)
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
Modulation of T-cell activation by malignant melanoma initiating cells.
T. Schatton (2010)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
M. Sznol (2013)
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping
M. Jesinghaus (2017)
International Agency for Research on Cancer.
H. Bartsch (1969)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
J. Taube (2012)
Tumor B7H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson (2006)
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression
M. Chen (2016)
Negative influence of programmed death‐1‐ligands on the survival of esophageal cancer patients treated with chemotherapy
K. Tanaka (2016)
IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells
E. Guenova (2015)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
K. Schalper (2014)
Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group
Hyeyoon Chang (2016)
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Y. Bang (2010)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger (2013)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst (2013)
A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2017
R R Core Team (2017)
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
M. Vassilakopoulou (2015)
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis
B. Huang (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Kim C. Ohaegbulam (2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
L. H. Schmidt (2015)
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
D. Kollmann (2017)
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
H. I. Jung (2017)
Programmed death‐ligand 1 expression at tumor invasive front is associated with epithelial‐mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma
S. Tsutsumi (2017)

This paper is referenced by
Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
Silvio Daester (2020)
Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche
P. Han (2020)
Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
G. Cioccoloni (2019)
Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival
Karl-Frederick Karstens (2020)
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
D. Vrána (2018)
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
I. Saulite (2020)
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Małgorzata Bobrowicz (2019)
PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Juliana Knief (2019)
Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study
Y. Imamura (2020)
Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Yandong Miao (2020)
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
A. Beer (2020)
Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
K. Yamashita (2020)
Lymph Node Blood Vessels: Exit Route for Systemic Dissemination of Cancer
R. Skopec (2018)
Semantic Scholar Logo Some data provided by SemanticScholar